| Comment type | Description |
|---|
| Alternative Products | Event=Alternative splicing; Named isoforms=2; Name=1; IsoId=P42330-1; Sequence=Displayed; Name=2; IsoId=P42330-2; Sequence=VSP_055798; Note=No experimental confirmation available.; |
| Biophysicochemical Properties | Kinetic parameters: KM=142.1 uM for progesterone ; KM=2.37 uM for 5-alpha-dihydrotestosterone ; KM=1.0 uM for androstanediol ; Vmax=20.1 nmol/min/mg enzyme with progesterone as substrate ; Vmax=1.8 nmol/min/mg enzyme with 5-alpha-dihydrotestosterone as substrate ; Vmax=4.4 nmol/min/mg enzyme with androstanediol as substrate ; |
| Catalytic Activity | (5Z,13E)-(15S)-9-alpha,11-alpha,15- trihydroxyprosta-5,13-dienoate + NADP(+) = (5Z,13E)-(15S)-9- alpha,15-dihydroxy-11-oxoprosta-5,13-dienoate + NADPH. |
| Catalytic Activity | A 3-alpha-hydroxysteroid + NAD(P)(+) = a 3- oxosteroid + NAD(P)H. |
| Catalytic Activity | Indan-1-ol + NAD(P)(+) = indanone + NAD(P)H. |
| Catalytic Activity | Testosterone + NAD(+) = androstenedione + NADH. |
| Catalytic Activity | Testosterone + NADP(+) = androst-4-ene-3,17- dione + NADPH. |
| Catalytic Activity | Trans-1,2-dihydrobenzene-1,2-diol + NADP(+) = catechol + NADPH. |
| Enzyme Regulation | Strongly inhibited by nonsteroidal anti- inflammatory drugs (NSAID) including flufenamic acid and indomethacin. Also inhibited by the flavinoid, rutin, and by selective serotonin inhibitors (SSRIs). |
| Function | Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta- PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone. |
| Sequence Caution | Sequence=BAA04619.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence= ; |
| Similarity | Belongs to the aldo/keto reductase family. |
| Subcellular Location | Cytoplasm. |
| Tissue Specificity | Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. The dominant HSD in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate. {ECO |
| Web Resource | Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/AKR1C3ID612ch10p15.html"; |